We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02223923
Recruitment Status : Unknown
Verified October 2019 by Royal Marsden NHS Foundation Trust.
Recruitment status was:  Active, not recruiting
First Posted : August 22, 2014
Last Update Posted : April 8, 2020
Cancer Research UK
RM/ICR Biomedical Research Centre
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

Brief Summary:

This study will investigate the use of a new drug targeting the DNA repair pathway AZD6738, an ATR inhibitor). Many tumours have lost important DNA repair functions and rely more heavily on a few remaining repair pathways to survive. Preclinical studies indicate that, in these tumours, preventing the function of the remaining pathways will lead to tumour cell death, while sparing normal cells. This study aims to investigate the safety and tolerability of the new drug in patients with advanced cancer, as well as in combination with palliative radiotherapy, where the drug may increase the effectiveness of radiotherapy by preventing repair of the radiationinduced DNA damage. As the drug has only been given to a small number of patients, the study will focus on safety and finding the correct dose to proceed to further studies, although preliminary signs of drug activity will also be examined.

The initial part of the study will administer increasing doses of the drug to groups of patients with advanced cancer who have no standard anticancer treatment options available. Testing will establish whether the drug levels in the body and tumour are adequate for the drug to have an effect, and any toxicity will be assessed. After the recommended dose is established, the recommended dose schedule will be stablished by trialing different schedules. Participants will be tested to see if their tumours lack the main DNA repair pathway (those who are predicted to have a better response to this drug). Finally, the drug will be given to patients with advanced cancer who require a course of radiotherapy for symptom control - the drug will be tested at different doses and with different doses of radiotherapy.

Side effects will be monitored and tests will establish whether the drug is enhancing the radiotherapy effect in the tumours or normal tissues.

Condition or disease Intervention/treatment Phase
Solid Tumour Refractory to Conventional Treatment Drug: AZD6738 Radiation: Palliative radiotherapy Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours
Study Start Date : July 2014
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Palliative Care

Arm Intervention/treatment
Experimental: Dose Escalation
AZD6738 PO 20 to 380mg BD increasing
Drug: AZD6738
Experimental: AZD6738 - Expansion Phase
AZD6738 starting dose and regimen to be determined in dose escalation phase
Drug: AZD6738
Experimental: AZD6738 + Radiotherapy (Head and Neck)
AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
Drug: AZD6738
Radiation: Palliative radiotherapy
Experimental: AZD6738 + Radiotherapy (Abdomen / Pelvis)
AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
Drug: AZD6738
Radiation: Palliative radiotherapy

Primary Outcome Measures :
  1. Identifying the maximum tolerated dose (MTD) of AZD6738 as a single-agent; and in combination with palliative radiation schedules. [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Determining causality of each adverse event in relation to AZD6738 and grading severity according to CTCAE version 4; [ Time Frame: 4 weeks ]
  2. Single and multiple dose pharmacokinetics: measurement of plasma levels of AZD6738 at pre-defined intervals in the dose-escalation part of the study in order to establish pharmacokinetic parameters; [ Time Frame: Day 0 and Day 1 ]
  3. Any response (stable disease, partial response or complete response) in any of the patients by physical, tumour marker and/or radiographic assessments of tumours as determined by RECIST 1.1. [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically documented solid tumour refractory to conventional treatment
  • Evidence of measurable or evaluable disease by RECIST 1.1
  • Age must be 18 years or over.
  • ECOG performance status 0-1 (part A); 0-2 (parts B and C)
  • Life expectancy of at least 3 months.
  • Patients must have normal organ and bone marrow function measured within 7 days prior to administration of study treatment as defined below:
  • Signed informed consent indicating that the subject is aware of the neoplastic nature of their disease and have been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts.
  • Willing and able to comply with scheduled visits, tissue sampling, treatment plan, and laboratory tests.
  • Able to swallow, absorb and retain oral medication.

Exclusion Criteria:

  • Therapy with any other investigational medical product (IMP) concurrently or within 28 days prior to signing of consent.
  • Pregnant or breast-feeding women.
  • Ability to become pregnant (or already pregnant or lactating).
  • Clinically significant cardiac disease including:
  • Known HIV positive or active hepatitis B or C infection
  • Uncontrolled active infection
  • Symptomatic and progressive or steroid-requiring brain metastases or leptomeningeal disease involvement.
  • Uncontrolled hypertension requiring clinical intervention, hypertension requiring 2 or more antihypertensive agents
  • Dementia or altered mental status that would prohibit informed consent.
  • Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the subject inappropriate for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02223923

Layout table for location information
United Kingdom
University College Hospital
London, United Kingdom, NW1 2BU
Guys and St Thomas' NHS Foundation Trust
London, United Kingdom, SE1 9RT
Royal Marsden Hospital
London, United Kingdom, SW3 6JJ
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Cancer Research UK
RM/ICR Biomedical Research Centre
Layout table for investigator information
Principal Investigator: Kevin Harrington, MBBS MRCP FRCR Institute of Cancer Research, United Kingdom
Principal Investigator: Martin Forster University College London Hospitals
Layout table for additonal information
Responsible Party: Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT02223923    
Other Study ID Numbers: CCR4087
First Posted: August 22, 2014    Key Record Dates
Last Update Posted: April 8, 2020
Last Verified: October 2019
Keywords provided by Royal Marsden NHS Foundation Trust:
Phase 1
Maximimum tolerated dose
ATR Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms